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TranscriptionTransglutaminase 2 (TG2) is a widely expressed and multifunctional protein that modulates cell death/
survival processes. We have previously shown that TG2 binds to hypoxia inducible factor 1β (HIF1β) and de-
creases the upregulation of HIF responsive genes; however, the relationship between these observations was
not investigated. In this study, we investigated whether endogenous TG2 is sufﬁcient to suppress HIF activity
and whether the interaction between TG2 and HIF1β is required for this suppression. shRNA-mediated si-
lencing of TG2 signiﬁcantly enhanced HIF activation in response to hypoxia. In addition, nuclear localization
of TG2 is required for its suppressive effect on HIF activity, with TG2 being recruited to HIF responsive pro-
moters in hypoxic conditions. These observations suggest that TG2 directly regulates hypoxic transcriptional
machinery; however, its interactionwith HIF1βwas not required for this regulation.We also examinedwhether
TG2's effect on cell death/survival processes in ischemia is due to its effects on HIF signaling. Our results indicate
that TG2 mediated HIF suppression can be separated from TG2's effect on cell survival in hypoxic/hypoglycemic
conditions. Lastly, here we show that nuclear TG2 in the closed conformation and non-nuclear TG2 in the open
conformation have opposing effects on hypoxic/hypoglycemic cell death, which could explain previous contro-
versial results. Overall, our results further clarify the role of TG2 in mediating the cellular response to ischemia
and suggest that manipulating the conformation of TG2 might be of pharmacological interest as a therapeutic
strategy for the treatment of ischemia-related pathologies.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Transglutaminase 2 (TG2, EC 2.3.2.13) is a multifunctional protein
[1] which, in addition to its role in catalyzing calcium-dependent
transamidation reactions [2], exhibits GTPase [3], protein disulﬁde
isomerase [4] and possibly even a protein kinase activity [5]. Further,
TG2 can regulate cellular function by binding to other proteins
resulting in a change in their activity and/or localization [6–8]. The
human transglutaminase (TG) family consists of 9 members, and
TG2 is the most ubiquitously expressed and most studied member
of the family [2]. Although TG2 plays a role in numerous cellular pro-
cesses, its function in regulating cell survival/death has been an area
of particular interest [9].inducible factor; HRE, hypoxia
D, oxygen glucose deprivation;
; CAT, catalytic; ChIP, chromatin
NA, short hairpin RNA; scrRNA,
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rights reserved.TG2 was originally considered to be a pro-cell death protein
[10,11], which certainly can be the case when its transamidating
activity is robustly increased [12,13]. However, it is increasingly ap-
parent that TG2 often plays a pro-survival role [8,12,14–17]. Interest-
ingly, in many cases the pro-survival effects of TG2 seem to be
independent of its transamidating activity [8,18–20]. There is also a
growing awareness that the subcellular localization plays a role in
determining the role of TG2 in cell survival processes [8,19]. Further-
more, the conformation of TG2 could be important for its role in cell
survival/death processes. TG2 is proposed to have open and closed
conformers, with notably distinct features [21,22]. The closed form is
used as an equivalent to the GTP/GDP bound form, which is thought to
be more compact than the open conformer. In a previous study, we
found that the open conformerwas toxic to immortalizedmouse striatal
neurons [23].
TG2 is primarily cytosolic, however the presence of TG2 in the nucle-
us iswell-documented [24,25].More interestingly, a pattern is emerging
where TG2 exhibits increased nuclear localization in response to cell
stress and this may be a protective response. Earlier reports suggested
that treatment with sphingosine [26], glutamate [27] or maitotoxin
[24] caused nuclear accumulation of TG2. More recently Tatsukawa
2 S. Gundemir et al. / Biochimica et Biophysica Acta 1833 (2013) 1–10et. al. demonstrated that the ethanol-induced stress in hepatic cells
resulted in signiﬁcant TG2 accumulation in the nucleus [28]. We [7,29]
and others [30] have shown that hypoxic/ischemic stress also signif-
icantly increases nuclear TG2 levels. Therefore, it is reasonable to
expect a functional outcome from this stress-induced nuclear accu-
mulation, and it is becoming evident that this outcome is most likely
transcriptional regulation [7,28–32].
Numerous studies have provided evidence that TG2 does indeed
modulate transcriptional processes. For example, TG2 attenuates AP-1
activation by binding to c-Jun which decreases its interaction with
c-fos [31], and in mutant huntingtin-expressing cells TG2 repressed
the expression of PGC-1α and cytochrome c [32]. TG2 also has been
reported to increase NF-κB activation in cancer cells [30,31,33]. We
have previously shown that TG2 accumulates in the nucleus in response
to hypoxic and ischemic stress in neurons; and it can interact with
hypoxia inducible factor 1β (HIF1β) and suppress HIF-dependent tran-
scription. HIFs are heterodimeric transcription factors which are in-
duced by hypoxia. Both subunits, α and β, are members of the PAS
(PER-ARNT-SIM) protein family which contain a basic helix–loop–
helix (bHLH) DNA binding domain [34–39]. In these ischemia models
increased TG2 expression was protective, and speciﬁcally targeting
TG2 to the nucleus enhanced this effect [7,19,29]. Recently, an exciting
study from our lab showed that, in contrast to TG2 expression in neu-
rons, astrocytic TG2 expression is detrimental to the survival of astro-
cytes and negatively impacts their ability to protect neurons from
ischemic insult [40]. The reasons for the cell type speciﬁc effects of
TG2 on survival in ischemic conditions are currently unknown and an
area of investigation.
In this study, we focused on dissecting the role of TG2 in hypoxic
signaling. We now demonstrate that knocking down endogenous
TG2 results in increased HIF signaling in neurons and in a human neu-
roblastoma cell line, SH-SY5Y. Using nuclear localization signal (NLS)
and nuclear export signal (NES) tagging of TG2 to manipulate the
levels of TG2 in the nucleus, we demonstrate that nuclear localization,
but not the transamidating activity, of TG2 is required for the sup-
pression of HIF signaling. Furthermore, using a chromatin immuno-
precipitation (ChIP) assay, we demonstrate that TG2 is recruited to
the hypoxia response element (HRE) bearing portion of the Enolase 1
promoter in hypoxic, but not normoxic conditions. This ﬁnding strongly
suggests that TG2 is in a position to control hypoxia responsive tran-
scription directly. We also show that the interaction between TG2 and
HIF1β is not required for TG2 to repress HIF dependent transcription.
Very intriguingly, the expression of the catalytic core domain of TG2,
which lacks transamidase activity, was enough to enhance oxygen
and glucose deprivation (OGD)-induced toxicity. This observation
suggests that the conformation, not the activity, of TG2 may be more
decisive in determining whether TG2 is pro-survival or pro-death in is-
chemia. Overall, this study strongly suggests that the role of TG2 in the
hypoxic response likely includes regulating hypoxia responsive tran-
scription by directly modulating the preinitiation complex responsible
for the transcription of HIF target genes. However, our data suggest
that its role in HIF signaling is unlikely to be sufﬁcient to explain its
role in ischemic cell death.
2. Materials and methods
2.1. Constructs
The NES vector was created by cloning the nuclear export signal
from PKI-α [41] into pcDNA 3.1 (+) (Invitrogen). Brieﬂy, the sequence:
5′-atcgctcgagcccaacagcaatgaattagccttgaaattagcaggtcttgatatcaacaag-
acagaataggggcccatcg-3′ was commercially synthesized, cloned into
pcDNA3.1(+) vector using the restriction enzyme sites XhoI and ApaI.
The resulting NES-pcDNA3.1(+) construct was veriﬁed by sequencing.
This vector was used previously in our lab to exclude another protein
from the nucleus [42]. The remaining constructs that were created aredescribed in Supplemental Table 1 and the primers used in this proce-
dure are described in Supplemental Table 2.
2.2. Cell culture
The preparation and treatment of the primary cortical neurons are
explained in Appendix A. HEK 293A cells were cultured in Dulbecco's
modiﬁed Eagle's medium (DMEM) (Irvine Scientiﬁc) supplemented
with 5% fetal bovine serum (HyClone); MCF-7 cells were cultured in
RPMI (Irvine Scientiﬁc) medium supplemented with 5% fetal bovine
serum; SH-SY5Y cells were cultured in RPMI medium supplemented
with 10% fetal bovine serum. All media were supplemented with
2 mM L-glutamine (Invitrogen, Life Technologies, Inc.), 100 μg/mL
streptomycin (Invitrogen, Life Technologies, Inc.) and 100 units/mL
penicillin (Invitrogen, Life Technologies, Inc.). Cells were grown in a hu-
midiﬁed atmosphere containing 5% CO2 at 37 °C. Transient transfections
were carried out using FuGENE 6 reagent (Roche Applied Science) or
Lipofectamine 2000 (Invitrogen) according to the manufacturers' in-
structions. The SH-SY5Y cells which overexpress TG2 were created as
described previously [43].
2.3. Cell treatment paradigms
24 h after transfection, the cells were transferred to serum-free
media and incubated in a humidiﬁed atmosphere at 37 °C containing
5% CO2 at the speciﬁed oxygen concentrations for the indicated lengths
of time. For the cell survival/death studies, cellsweremaintained at 0.1%
oxygen and no glucose (complete OGD); mild OGD refers to treatment
in 0.2% oxygen and 2.8 mM glucose. Control cells were maintained in
serum free control media (25 mM glucose) and ambient oxygen. For
the measurement of HIF activity, cells were incubated in serum free
control media at 0.1% oxygen for the indicated lengths of time. Control
cells weremaintained in serum free controlmedia and ambient oxygen.
For XRE luciferase assay, cells were transferred to serum free control
media and treated with 10 μM 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD, dioxin) for 12 h in a humidiﬁed atmosphere at 37 °C containing
5%CO2 and ambient oxygen. Immediately after the incubation the activ-
ity of the reporter was measured. Control cells were treated with vehi-
cle alone, dimethyl sulfoxide (DMSO).
2.4. Dual luciferase assay
The HRE luciferase assay was carried out as described previously
[19]. For the XRE luciferase assay, the MCF-7 cells were plated in a
24-well plate and transiently transfected with the TG2 constructs to-
gether with a luciferase vector under control of an XRE-bearing frag-
ment from the CYP1A1 promoter (a generous gift from Dr. S. Kato)
and a Renilla luciferase vector control [7] using FuGENE 6 reagent as de-
scribed above. 24 h post-transfection, cells were transferred to serum
freemedia and treatedwith TCDD or DMSO as described above. Lucifer-
ase activity was measured in cellular lysates using the Dual-Luciferase
Reporter Assay System Kit (Promega, Madison, WI, USA) according to
the manufacturer's protocol and a TD-20/20 Luminometer. For each
sample, the luciferase reporter data were normalized to the Renilla lu-
ciferase internal control.
2.5. Real time PCR
Following total RNA isolation, cDNA was synthesized using Super-
script III ﬁrst strand synthesis kit (Invitrogen) with oligo-dT primers
according to the manufacturer's instructions. Real time PCR was
conducted using Taqman gene expression system (Applied Biosci-
ences) and Taqman primers for TG2 (Hs00190278_m1), BNIP3
(Hs00969291_m1), ENO1 (Hs00361415_m1), NOXA (Hs00560
402_m1), EPO (Hs00171267_m1), VEGFA (Hs00173626_m1) and
β-actin (Hs99999903_m1). Data was analyzed using the ΔΔCt
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The LDH release assay was carried out as described previously
[19]. The calcein AM assay was modiﬁed from Ruan et. al. [44]. Calcein
AM was dissolved in DMSO and was used at a ﬁnal concentration of
2 μM in the cell media. It was incubated with the cells for 1 h and
the ﬂuorescent signal recorded using 485 nm excitation wavelength
and 530 nm emission wavelength. The results are expressed relative
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Nuclear fractionation studies were carried out as previously de-
scribed [19]. The only modiﬁcation was the ﬁnal step, in which the
crude nuclei were overlaid on the top of 0.5–0.7 M sucrose with pro-
tease inhibitors, and spun at 1200 ×g for 10 min at 4 °C for the
HEK-293A cells and 2000 ×g for 20 min at 4 °C for the MCF cells.
Please see the Supplementary information section for the remain-
der of the Materials and methods.25
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Fig. 1. TG2 regulates HIF activity in rat primary cortical neurons. (a) Endogenous TG2 is
sufﬁcient to suppress HIF activity in neurons. Primary neurons were transduced with hTG2
or TG2-shRNA viral particles prior to treatment with DFO for 24 h (chemical hypoxia) and
measurement of HRE luciferase reporter activity. Increased TG2 expression signiﬁcantly
suppressed HRE activity (~50%) whereas knocking down endogenous TG2 signiﬁcantly
increased HRE activity (N=3). (b) Nuclear localization of TG2 is required to suppress HIF
activity in neurons. Primary neurons were transiently transfected with control, untagged,
NLS-tagged or NES-tagged TG2 constructs and the HRE and Renilla luciferase reporter con-
structs prior to chemical hypoxia and HRE activity measures as in (a). The untagged and
NLS-tagged TG2 signiﬁcantly suppressedHRE activity ~40%. NES-tagged TG2 signiﬁcantly in-
creasedHRE activity ~20% (N=5). (c) Transamidase activity of TG2 is not involved in theHIF
suppression inneurons. Primaryneuronswere transiently transfectedwith control,wild type
TG2, C277S-TG2 orW241A-TG2 constructs and the HRE and Renilla luciferase reporter con-
structs prior to chemical hypoxia and HRE activity measures as in (a). Both the C277S and
W241Amutations abolish the transamidating activity of TG2. All three TG2 constructs signif-
icantly suppressed chemical hypoxia induced HIF activity relative to the control (N=4).
Results are shown as mean±SEM *pb0.05, **pb0.01.3. Results
3.1. TG2 regulates HRE activity in rat primary cortical neurons
In our previous studies we showed that TG2 overexpression in
neurons signiﬁcantly decreased ischemic cell death in situ [7] and in-
farct volumes in vivo [29]. Therefore we examined the effects of TG2
on HIF signaling in primary neurons. Rat primary neurons were
infected with either a lentivirus encoding human TG2 or the shRNA
for TG2. As a control, neurons were transduced with control viral par-
ticles containing empty lentiviral vector. All the transduced neurons
were subsequently transfected with HRE luciferase and renilla lucifer-
ase (internal control). 24 h after transfection, neurons were treated
with 100 μM desferrioxamine (DFO) to stabilize HIF1α and increase
HIF signaling. DFO had no signiﬁcant effect on neuronal survival at
this concentration (data not shown). DFO treatment and oxygen dep-
rivation result in similar increases in the expression of HIF responsive
genes [45,46]. Data is presented as percent HRE reporter activity rel-
ative to control. TG2 overexpression in rat primary neurons reduced
the HRE reporter activity ~50% compared to its own control and
knocking down endogenous TG2 potentiated HRE reporter activity
approximately 2 fold over the control (Fig. 1a). When neurons were
transfected with untagged TG2 or NLS-tagged TG2 along with HRE lu-
ciferase and renilla luciferase vectors and subsequently treated with
DFO, HRE activity was decreased in a manner similar to what was ob-
served when the neurons were infected with TG2. Also, as expected,
the suppression of HRE activity was lost when the exogenously
expressed TG2 was tagged with an NES (Fig. 1b). To determine if
transamidation activity is required for the suppression of HRE activity
in rat primary neurons, the C277S-TG2 and W241A-TG2 constructs
were used, both of which lack transamidating activity. These studies
demonstrated that C277S-TG2 and W241A-TG2 suppressed HRE re-
porter activity signiﬁcantly relative to the empty vector (Fig. 1c).
These results show that in neurons, endogenous TG2, as well as exog-
enously expressed TG2, suppress HRE activation and that TG2 must
localize to the nucleus to downregulate HRE activity. Further, the
transamidation activity of TG2 is not required for the suppression of
HRE activity in rat primary neurons. These data are in agreement
with the results that we have obtained with cell lines as discussed
below.3.2. TG2 regulates HIF activity and OGD-induced cell death in human
neuroblastoma cells
Data shown in Fig. 1 clearly demonstrates that endogenous TG2
attenuates HRE activity in rat primary neurons in response to DFO,
4 S. Gundemir et al. / Biochimica et Biophysica Acta 1833 (2013) 1–10which is often used to increase HIF activity [45,46]. However, in
primary rat neurons we were unable to detect any increase in HRE ac-
tivity using HRE luciferase reporters in response to oxygen depriva-
tion, even though we tried numerous different paradigms (data not
shown). Therefore, we used another cell type to determine whether
endogenous TG2 can modulate HIF signaling in response to oxygen
deprivation (i.e., true hypoxia). To this end, we used a human cell
line of neuronal origin in order to analyze the ability of TG2 to mod-
ulate HIF signaling. In the ﬁrst series of experiments, we knocked
down endogenous TG2 by lentiviral delivery of a shTG2 construct to
human neuroblastoma SH-SY5Y cells. In initial studies, the efﬁciency
of TG2 knockdown with the lentiviral constructs was determined by(a)
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Fig. 2. TG2 regulates HIF activity and ischemic cell death in human neuroblastoma cells. (a
luciferase activity in SH-SY5Y cells after 20 h of 0.1% oxygen treatment compared to normo
Depleting endogenous TG2 by shRNA (TG2 knockdown) signiﬁcantly increased HRE-driv
human TG2 (TG2 addback) (N=5). (b) Depleting endogenous TG2 decreases survival afte
after 20 h of 2.8 mM glucose and 0.2% oxygen treatment as determined by the calcein-AM
genes in SH-SY5Y cells. Fold induction in the expression of certain HIF target genes at the mR
endogenous TG2 by shRNA signiﬁcantly increased the expression of EPO, ENO1, VEGF and BN
SH-SY5Y cells in response to hypoxia. Representative agarose gel electrophoresis results fro
promoter of human Eno1 gene in response to 16 h of 0.1% oxygen treatment. Results are shtransducting naïve SH-SY5Y human cells and SH-SY5Y cells stably
overexpressing human TG2 with shRNA for TG2 [47] at two different
dilutions (1:2 and 1:10 as described in the Materials and methods
section), or with a scrambled shRNA (scrRNA) [47] at one dilution
(1:2) and subsequently collected and immunoblotted. TG2 immuno-
blots from naïve cells were exposed for a longer period of time to vi-
sualize the endogenous TG2 compared to the TG2 overexpressing
cells. The data demonstrate that TG2-shRNA efﬁciently knocked down
both endogenous and exogenous TG2. Tubulin was used as a loading
control (Fig. C1). The data was quantiﬁed by histogram analysis and it
was found that the TG2 expressionwas decreased by ~51% at 1:10 dilu-
tion and ~85% at 1:2 dilution (Fig. C1). After conﬁrming that the knockscrambledRNA
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*
+ + 
−     + 
neg: no 1o Ab
HIF1β Ab
TG2 Ab
pos: histones Ab
***
ENO1 BNIP3
shRNA scrambledRNA
%
 s
ur
viv
al
 o
ve
r n
or
m
ox
ia
0
10
20
30
40
50
60
b)
) Endogenous TG2 is sufﬁcient to suppress HIF activity in SH-SY5Y cells. Relative HRE
xia. Data is presented as percent of scrambled RNA or empty vector infection controls.
en luciferase activity and this activation was reversed by heterologous expression of
r mild OGD in SH-SY5Y cells. Percent survival compared to normoxia/normoglycemia
assay in SH-SY5Y cells. (N=7). (c) Depleting endogenous TG2 upregulates HIF target
NA level following 6–12 h of 0.1% oxygen treatment determined by qRT-PCR. Depleting
IP3 (N=3). (d) TG2 is recruited to the HRE spanning portions of the Eno1 promoter in
m chromatin immunoprecipitation (ChIP) experiments (N=3). TG2 is recruited to the
own as mean±SEM *pb0.05, **pb0.01.
(a)
25
50
75
125
0
100
wt-TG2
W241A-TG2
**
**
(b)
25
50
75
125
150
175
0
100
200
wt-TG2
W241A-TG2 *
**
%
 lu
cif
er
as
e 
ac
tiv
ity
 
re
la
tiv
e 
to
 e
m
pt
y 
ve
ct
or
%
 lu
cif
er
as
e 
ac
tiv
ity
 
re
la
tiv
e 
to
 e
m
pt
y 
ve
ct
or
untagged NLS-tagged NES-tagged
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Fig. 3. Nuclear localization, but not transamidase activity, of TG2 is required to sup-
press HIF activity in different human cell lines. (a) Nuclear localization of TG2 is re-
quired to suppress HIF activity in HEK cells. Relative HRE luciferase activity in
HEK-293A cells transiently transfected with TG2 constructs after 15 h of 0.1% oxygen
treatment. Data is presented as percent of empty vector controls. NLS-tagged TG2 sig-
niﬁcantly suppressed HRE activity; whereas untagged and NES-tagged TG2 had no
effect. The effect of the transamidating inactive TG2 (W241A-TG2) was the same as
wild type TG2 (N=4). (b) Nuclear localization of TG2 is required to suppress HIF activ-
ity in MCF-7 cells. Relative HRE luciferase activity in MCF-7 cells transiently transfected
with TG2 constructs after 15 h of 0.1% oxygen treatment. Data is presented as percent
of empty vectors. NES-tagged TG2 signiﬁcantly induced HRE activity. The effect of
the transamidating inactive TG2 (W241A-TG2) was the same as wild type TG2 (N=4).
Results are shown as mean±SEM *pb0.05, **pb0.01.
5S. Gundemir et al. / Biochimica et Biophysica Acta 1833 (2013) 1–10down was efﬁcient, naïve human SH-SY5Y neuroblastoma cells trans-
ducedwith TG2-shRNAor scrRNAwere transfectedwith anHRE lucifer-
ase reporter and a Renilla control construct and 24 h later, the cells
were incubated for 20 h at 0.1% oxygen. Following incubation, the tran-
scriptional activity was monitored by an HRE luciferase assay. The re-
sults shown in Fig. 2a demonstrate that knocking down TG2 levels by
shRNA signiﬁcantly increased HRE-driven transcription in response to
hypoxia as determined by the luciferase assay. When we transfected a
human TG2 (addback) construct together with the HRE luciferase con-
struct before hypoxic treatment, the increase in luciferase activity was
attenuated (Fig. 2a). To determine if endogenous TG2 positively or neg-
atively affects cell survival in hypoxic/hypoglycemic conditions in addi-
tion to its negative effect on HIF activity, naïve SH-SY5Y cells were
transduced as described above prior to OGD. For these studies we
used 0.2% oxygen and 2.8 mM glucose (~10% of the amount in regular
media), which we refer to as ‘mild OGD’ for 20 h. Cell survival/death
was monitored by calcein AM assay. As shown in Fig. 2b, depleting en-
dogenous TG2 by shRNA signiﬁcantly reduced cell survival in SH-SY5Y
cells in response to mild OGD. These results demonstrate that endoge-
nous TG2 is sufﬁcient to suppress HIF signaling and protect the neuro-
blastoma cells against OGD-induced cell death. HIF can induce both
pro-survival and pro-death genes; therefore it is difﬁcult to predict
the overall effect of HIF suppression on cell survival. A selective sup-
pression of pro-death HIF responsive genes might explain why TG2
is protective in this cell line. To test this possibility, we screened a
small subset of HIF responsive genes. For this purpose, naïve human
SH-SY5Y neuroblastoma cells infected with TG2-shRNA or scrRNA
were incubated at 0.1% oxygen for 6–12 h. Following incubation, the
transcriptional activity was monitored by Q-RT-PCR analysis of several
HIF responsive genes. Depleting endogenous TG2 by shRNA signiﬁcant-
ly increased the expression of EPO, ENO1, VEGF and BNIP3 (Fig. 2c) in-
dicating a lack of selectivity in the regulation of HIF responsive gene
expression. We also checked the expression of Noxa but we did not de-
tect a hypoxic upregulation of this gene (data not shown). To further
elucidate the mechanisms by which TG2 suppresses HIF-dependent
transcription, we next examined if TG2 is recruited into the complex
that forms on HRE-bearing promoters in response to hypoxia. To this
end, we used ChIP with primers that amplify ~150–200 bp portions
from the promoters of human Eno1, BNIP3 and Noxa genes that bear
functional HREs. As shown in Fig. 2d, TG2was recruited to the promoter
of human Eno1 gene in response to 16 h of 0.1% oxygen treatment,
while only trace amounts of TG2 could be detected in normoxic sam-
ples. Immunoprecipitation of histones was used as a positive control
(Fig. 2d). TG2 was also found on the human Bnip3 promoter after 6 h
of 0.1% oxygen, however we did not detect TG2 at the HRE bearing por-
tion of the Noxa promoter in any of the conditions that were used (data
not shown).
3.3. Nuclear localization, but not transamidase activity, of TG2 is
required to suppress HIF activity in different human cell lines
The fact that TG2 is physically present on HRE bearing promoters
in hypoxia clearly suggests that it might be directly affecting the
HIF-dependent transcriptional machinery. In order to further delin-
eate this possibility, we designed an experiment in which we manip-
ulated the nuclear TG2 amount by expressing it with an NLS or an NES
tag. According to our rationale, if TG2 is suppressing HIF activity at
the transcriptional machinery, there should be an inverse correlation
between the nuclear TG2 amounts and the HIF activity. We carried
out these studies in two human cell lines; HEK-293A (Fig. 3a) and
MCF-7 (Fig. 3b) cells. These cell types, unlike SH-SY5Y cells, have lowen-
dogenous TG2 levels and therefore are better models for overexpression
studies. HEK-293A and MCF-7 cells were transiently transfected with
TG2 and luciferase constructs and 24 h post-transfection the cells were
treated with 15 h of 0.1% oxygen. In HEK-293A cells, there were only
trace amounts of TG2 in the nucleus in both normoxic and hypoxicconditions unless the TG2 that was expressed was speciﬁcally localized
to the nucleuswith anNLS-tag (data not shown). In linewith this obser-
vation and our previous studies [19], NLS-tagged TG2 signiﬁcantly
suppressed HRE activity; whereas untagged and NES-tagged TG2
had no effect (Fig. 3a). The same treatment paradigm was used in
MCF-7 cells. In contrast to HEK-293A cells, untagged TG2 showed signif-
icant nuclear localization even under normoxic conditions (Fig. C2). In
MCF-7 cells both untagged and NLS-tagged TG2 tended to suppress
HRE activity without reaching statistical signiﬁcance. However, NES-
tagged TG2 not only reversed this suppression, but resulted in a signiﬁ-
cant increase in HRE activity relative to vector controls (Fig. 3b) (NES tag
was conﬁrmed to successfully export TG2 out of the nucleus by cellular
fractionation studies; see Fig. C2). The effects of TG2 on HRE activity
were not dependent on transamidating activity, as a transamidating
inactive form of TG2 (W241A) was as effective as the wild type in
suppressing HRE activity (Fig. 3a and b). These results clearly show
that there is an inverse correlation between the nuclear TG2 levels and
HIF activity.
3.4. All domains of TG2 are required for maximal transamidase activity
We previously demonstrated that TG2 interacts with HIF1β and
suppresses HIF transcriptional activity [7,19]. However, it was not clear
whether there is a link between these two observations. To determine
6 S. Gundemir et al. / Biochimica et Biophysica Acta 1833 (2013) 1–10whether the TG2-HIF1β interaction is required for the TG2-dependent
suppression of HIF signaling, we wanted to determine the interacting
domain of TG2withHIF1β. To this end, wemade several TG2 constructs
that lack certain domains and measured their in vitro transamidase
activities prior to using them in our assays. The TG2 deletion constructs
were made based on well deﬁned domains within the protein [48].
Diagrams of these constructs are shown in Fig. 4a, and their maximal
in vitro transamidase activities are shown in Fig. 4b. As expected, the
catalytic core domain deletion causes a complete loss of transamidase
activity of TG2. Also, N-terminal β sandwich domain was proved to be
indispensible for the activity; however constructs lacking C-terminal
β barrels retained some activity. Nevertheless, it should be noted
that the deletion of β barrel domains also impairs guanine nucleotide
binding; therefore, the in situ activity proﬁles of the C-terminal deletion
construct could be different than the in vitro proﬁles.(a)
β-sandwich
catalytic
β-barrel1
β-barrel2
em
pt
y 
ve
ct
or
TG
2 
fu
ll 
le
ng
th
TG
2 
de
lta
 ß
sa
nd
%
 a
ct
ivi
ty
 o
f f
ul
l le
ng
th
0
20
40
60
80
100
120
(b)
Fig. 4. All domains of TG2 are required for maximal transamidase activity. (a) The schem
well-deﬁned domains of TG2 which were determined by its crystal structure [48]. (b)
transamidase activity of TG2. HEK-293A cells were transfected with V5-tagged TG2 deletio
was detected by an ELISA based assay and the results are presented as percent of full lengt3.5. Deletion of the catalytic domain of TG2 abolishes the interaction
between TG2 and HIF1β
GST pull-down assays were used to determine the interactions be-
tween the constructs in vitro and co-immunoprecipitation studies
were conducted to conﬁrm the results. For the GST pull-down exper-
iment, GST-HIF1βwas expressed and used in the pull down assay after
removal of the GST tag by PreScission Protease treatment as shown in
Fig. C3b. GST-pull-down assayswere carried out using theGST-TG2 con-
structs (Fig. C3a) as bait and HIF1β (Fig. C3b) as prey. The results shown
in Fig. 5a demonstrate thatHIF1βwaspulled down byGST-TG2 (lane 2),
GST-TG2Δβ-barrel1 (lane 5), and GST-TG2Δβ-barrel2 (lane 6); but not
by GST alone (lane 1) or GST-TG2ΔCAT (lane 4). HIF1β was pulled
down by GST-TG2Δβ-sandwich, but to a lesser extent (lane 3). These
data indicate that the catalytic domain of TG2 is required for HIF1βTG2 full length
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Fig. 5. Interacting with HIF1β is not required for TG2 to suppress HIF-dependent tran-
scription. (a) TG2 and HIF1β interact in vitro through the catalytic core domain of TG2.
Representative immunoblot from a GST pull-down assay with GST-TG2 variants as bait
and HIF1β as prey. Immunoblot analysis for HIF1β conﬁrms that HIF1β was pulled
down by full length GST-TG2 (lane 2), GST-TG2Δβ-barrel1 (lane 5), and GST-TG2
Δβ-barrel2 (lane 6); but not by GST alone (lane 1) and GST-TG2ΔCAT (lane 4).
HIF1β was pulled down by GST-TG2Δβ-sandwich to a lesser extent (lane 3). (b) TG2
and HIF1β interact through the catalytic core domain of TG2 in human cells. Represen-
tative immunoblot from a co-immunoprecipitation assay with V5-TG2 variants as bait
and myc-HIF1β as prey. HEK-293A cells were transfected with V5-tagged TG2 deletion
constructs and the myc-HIF1β construct. The cells were lysed after 48 h. Immunoblot
analysis for myc conﬁrms that HIF1β interacts with full length V5-TG2 (lane 2),
V5-TG2Δboth-β-barrels (lane 5), V5-TG2Δβ-barrel2 (lane 6), and V5-TG2-CAT alone
(lane 7); but not by V5 tag alone (lane 1), V5-TG2Δβ-sandwich (lane 3), and V5-TG2
ΔCAT (lane 4). (c) Interacting with HIF1β is not required for TG2 to suppress
HIF-dependent transcription. Relative HRE luciferase activity in MCF-7 cells transiently
transfected with NLS-TG2 constructs after 15 h of 0.1% oxygen treatment in the pres-
ence of 2.5 μM NC9. Data is presented as percent of empty vectors. NLS-tagged TG2
full length, TG2Δβ-sandwich and TG2ΔCAT constructs signiﬁcantly suppressed HRE
activity; however, NLS-tagged TG2Δboth-β-barrels, TG2Δβ-barrel2 and TG2-CAT alone
constructs signiﬁcantly induced HRE activity (N=4). Results are shown as mean±SEM
*pb0.05, **pb0.01, ***pb0.005.
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from TG2 impaired the interaction with HIF1β, possibly because of
the steric hindrance caused by the β barrel domains in the absence ofthe β sandwich domain. For the co-immunoprecipitation assay, the
V5-TG2 variants were used as bait and the myc-HIF1β as prey.
HEK-293A cells were transfected with V5-tagged TG2 deletion con-
structs and the myc-HIF1β construct and the assay was conducted
48 h post-transfection. The results shown in Fig. 5b demonstrate that
HIF1β interacts with full length V5-TG2 (lane 2), V5-TG2Δboth-
β-barrels (lane 5), V5-TG2Δβ-barrel2 (lane 6), and V5-TG2-CAT alone
(lane 7); but not with V5 tag alone (lane 1), V5-TG2Δβ-sandwich
(lane 3), and V5-TG2ΔCAT (lane 4). The interaction between the cata-
lytic domain alone with HIF1β (lane 7) is direct evidence which sug-
gests that the catalytic core domain is the interacting domain.
3.6. Interacting with HIF1β is not required for TG2 to suppress
HIF-dependent transcription
After identifying the domain of TG2 required for interaction with
HIF1β, we used this information to determine whether the interac-
tion between TG2 and HIF1β is required for TG2 to modulate HIF-
dependent transcription. To examine the effects of the TG2-HIF1β in-
teraction on TG2-modulated transcription and to avoid confounding
variables such as differential nuclear localization, we constructed
the TG2 deletion variants as NLS-tagged proteins in mammalian
expression vectors for these studies. MCF-7 cells were transiently
transfected with NLS-TG2 full-length and deletion constructs. Again,
in order to avoid other confounding variables, such as differential
activities and the conformations of the deletion constructs, we used
the irreversible TG inhibitor NC-9, which inhibits all activity and locks
the protein in the open conformation [23]. Cells were transfected with
TG2 and luciferase constructs and 24 h post-transfection they were
treated with 15 h of 0.1% oxygen in the presence of 2.5 μM NC-9. The
results are shown in Fig. 5c. NLS-tagged TG2 full length, TG2
Δβ-sandwich and TG2ΔCAT, which cannot interact with HIF1β, signiﬁ-
cantly suppressed HRE activity (Fig. 5c). Very intriguingly, NLS-tagged
TG2Δboth-β-barrels, TG2Δβ-barrel2 and TG2-CAT alone constructs
signiﬁcantly activated HRE (Fig. 5c). Overall, this result suggests
that, interacting with HIF1β is not required for TG2 to suppress HIF-
dependent transcription.
3.7. Conformation and localization of TG2 is important in determining its
role in OGD-induced cell death
HEK-293A cells were transfected with untagged, NLS-tagged and
NES-tagged TG2 constructs and 24 h post-transfection they were treat-
ed with 20 h of 2.8 mM g/L glucose and 0.2% oxygen. OGD-induced
toxicity was measured with the LDH release assay and the data are
presented as a percent of control (empty vector). For the ﬁrst part
of the cell death study,we usedwild type TG2, a transamidating inactive
mutant (W241A)which is in the closed conformation [19,21] and amu-
tant that does not bind GTP and thus is more prone to attain open con-
formation and exhibit increased transamidating activity in situ (R580A)
[19,21]. LDH release was signiﬁcantly decreased in cells which express
NLS-taggedW241A-TG2;whereas, NES-tagged R580A [49] signiﬁcantly
increased ODG-induced toxicity (Fig. 6a). Untagged-R580A tended
to increase toxicity without reaching statistical signiﬁcance (Fig. 6a).
For the second part of this study, we used full length V5-TG2, V5-TG2
ΔCAT and V5-TG2-CAT alone constructs with or without an NLS tag.
Only the V5-TG2-CAT alone construct without an NLS tag signiﬁcantly
increased OGD-induced toxicity; none of the other constructs signiﬁ-
cantly changed LDH release.
3.8. TG2 has no effect on xenobiotic responsive transcription
In addition to the HIF pathway, HIF1β is an important player in xe-
nobiotic responsive transcription [50]. Given that TG2 binds HIF1β,
TG2 could also attenuate xenobiotic response element (XRE) signaling;
thereforewemeasured the effects of TG2 on XRE activity inMCF-7 cells.
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Fig. 6. Effect of conformation and localization of TG2 on survival under OGD-induced
stress in HEK-293A cells. (a) Nuclear closed TG2 and non-nuclear open TG2 have
opposing effects on survival in OGD. LDH release in HEK-293A after 20 h of mild
OGD conditions. Data is normalized to normoxic/normoglycemic group and presented
as percent of empty vector. LDH release is signiﬁcantly decreased in HEK-293A cells
which express NLS-tagged W241A-TG2; whereas, NES-tagged R580A-TG2 signiﬁcantly
increased LDH release. (N=6). (b) Non-nuclear expression of the catalytic domain of
TG2 signiﬁcantly enhances OGD-induced toxicity. LDH release in HEK-293A after
20 h of mild OGD conditions. Data is normalized to normoxic/normoglycemic group
and presented as percent of empty vector. LDH release is signiﬁcantly increased in
HEK-293A cells which express V5-TG2 CAT alone. (N=6). Results are shown as mean±
SEM *pb0.05, **pb0.01, ***pb0.005.
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for 12 h [51] resulted in a ~3 fold induction in XRE luciferase activity
compared to the vehicle alone (data not shown). However, none of
the TG2 constructs had any signiﬁcant effect on XRE activity (Fig. C4).
4. Discussion
Although we had previously shown that exogenous TG2 decreases
HIF activity in human cell lines, in this study we demonstrate for the
ﬁrst time that endogenous TG2 also suppresses HIF signaling in rat
primary neurons and in a human neuroblastoma cell line giving a
strong physiological relevance to our ﬁndings. We also show that
TG2 must localize to the nucleus to suppress HIF activity and that
TG2 is recruited to the HRE preinitiation complex. Further, nuclear lo-
calization, but not activity, of TG2 is essential for protection against
OGD-induced cell death. In addition to these ﬁndings, we demon-
strate that the catalytic domain of TG2 is required for its interaction
with HIF1β; however this domain is neither necessary nor sufﬁcient
for TG2 to suppress HIF activity. On the other hand, the C-terminal
β-barrel 2 domain does appear to be essential for TG2 to suppress
HIF activity. These data suggest that the binding of HIF1β and TG2
and the ability of TG2 to suppress HIF activity are independent events.
HIF is composed of two subunits: a constitutively expressed β
subunit (HIF1β), and the oxygen sensing HIFα subunit [52]. The
HIF1α and HIF2α are structurally similar in their DNA binding anddimerization domains but differ in their transactivation domains
and regulate unique target genes [53,54]. In our previous report we
demonstrated that overexpressed TG2 suppressed both HIF1 and
HIF2 dependent transcription [7]. In this study, we examined the ef-
fects of TG2 on expression levels of both HIF1 and HIF2 targets in
SH-SY5Y cells. ENO1 [53], and BNIP3 [55] are primarily targets for
HIF1α, while EPO is preferentially regulated by HIF2α [56]. VEGF
can be regulated by both HIF1α and HIF2α [53]. EPO and VEGF
were highly upregulated in response to hypoxia, whereas ENO1 and
BNIP3 were upregulated to a lesser extent. These results suggest
that HIF2α may play a more prominent role in HIF signaling in
SH-SY5Y cells, which is a neuroblastoma cell line. This is in line with a
previous report which demonstrated the relevance of HIF2α in neuro-
blastoma models [57]. Nonetheless the hypoxia-induced expression of
all HIF responsive genes we have examined thus far signiﬁcantly in-
creased when TG2 is knocked down. Overall, these results clearly
show that endogenous TG2 modulates the transcription of HIF target
genes. We examined both prodeath (BNIP3) and prosurvival (EPO and
VEGF) genes in this study in order to see if TG2 has a selective effect.
From our limited set of genes, we could not detect any selective sup-
pression which could tip the balance of survival and death in one direc-
tion; therefore the biological signiﬁcance of TG2 mediated HIF
suppression is not clear in the context of ischemic cell death.
The most straightforward mechanism for this suppression would
be direct regulation of the transcriptional machinery forming on the
HRE bearing promoters. The results of the ChIP assay (Fig. 2d) clearly
show that endogenous TG2 is recruited to the HRE spanning portions
of HIF target genes in response to hypoxia in SH-SY5Y cells. The re-
cruitment was only observed in hypoxic conditions, which strongly
indicates that this recruitment has functional outcomes. Furthermore,
we failed to detect any TG2 on the Noxa promoter in either hypoxic or
normoxic conditions, which argues for speciﬁcity and functionality.
An important question is whether the conformation of TG2 is important
for the recruitment to promoters. Althoughwe lack direct evidence, the
likely answer is no; the deletion constructs (except the ones that lacked
the β-barrel2 domain), which without question lack the native open or
closed conformation of the full length protein, still suppressedHIF activ-
ity. If the recruitment to the promoter is necessary for HRE suppression,
this observation clearly shows that β-barrel2, not the conformation of
the protein is crucial in this phenomenon.
The presence of TG2 in the preinitiation complexes has also been
shown in other models. For example, in the presence of mutant
huntingtin, TG2 localizes to the promoters for cytochrome c and
PGC-1α [32]. Although TG2 is at HRE containing promoters, the
exact mechanism by which TG2 is repressing HIF activity is still being
investigated. At this point we speculate that TG2 is either mediating
the recruitment of certain corepressors or preventing the recruitment
of certain coactivators. If TG2 is suppressing HIF activity at the promoter
of HIF responsive genes, an inverse correlation between the nuclear TG2
amounts and the HIF activity should be expected. The results shown in
Fig. 3 strongly indicate that there is indeed an inverse correlation.
Whether there is a relationship between the TG2-HIF1β interaction
and TG2-mediated HIF suppression has been a fundamental question
for our studies. To this end, we have demonstrated that the HIF1β
interacting domain of TG2 is within its catalytic core domain (Fig. 5a
and b). Further, our results suggest that the interaction between HIF1β
andTG2 is not required for TG2 to suppress HIF-dependent transcription
(Fig. 5c). The failure of TG2 to inﬂuence another HIF1β dependent path-
way, namely xenobiotic responsive transcription (Fig. C4), supports
the conclusion that the TG2-HIF1β interaction is not essential per se
for transcriptional repression. However, this interaction might have
other physiological roles. For example we have preliminary evidence
suggesting that this interaction might be important for the nuclear
accumulation of TG2 in hypoxia (data not shown). The questionwheth-
er HIF1β binding affects in situ transamidating activity of TG2 is an in-
teresting one. However, given that the transamidating activity of
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to our studies and we did not examine this possibility.
TG2 can differentially affect a signaling process in a cell type speciﬁc
manner. Therefore it is crucial to exercise caution when interpreting
data obtained through the use of more than one cell line. In this study
we have used several cell models and the amount of nuclear TG2 varies
greatly between the cell lines used. However if we manipulate nuclear
TG2 amounts using genetic approaches, the outcome is very similar.
This observation suggests that the mechanism of HRE suppression by
TG2 is conserved among cell types and the amount of TG2 in the nucleus
is the variable that determineswhether TG2 suppresses HIF signaling or
not. This common response among various cell types is informative in
this regard. Therefore, using more than one cell line has advantages,
as well as drawbacks. In a similar trade-off situation, we had to choose
whether to manipulate the nuclear TG2 amounts through mutating
the proposed endogenous NLS residues in the protein or by adding ex-
ogenous NLS and NES signals. Both approaches have its merits and
drawbacks; however,mutating the endogenousNLS sitesmay have sec-
ondary unforeseeable effects on HIF signaling other than changing the
localization of the protein. Furthermore, the presence of endogenous
NLS sites in TG2 has not been unequivocally conﬁrmed experimentally
[32]. Therefore, the nuclear TG2 amounts were manipulated by exoge-
nous tags in this study. It should be noted that this approach does not
allow us to titrate the TG2 amounts in the nucleus; rather the use of
NLS and NES tagged constructs allows us to relatively increase or de-
crease the nuclear TG2 amounts compared to the untagged constructs.
Since we lack the tools to quantitatively manipulate nuclear TG2
amounts, we are unable to test whether there is a linear relationship be-
tween nuclear TG2 amounts and survival in OGD.
The depletion of endogenous TG2 not only upregulated HIF target
genes, but also decreased the survival of SH-SY5Y cells in response to
OGD. However it still needs to be establishedwhether or not there is a
causal relationship between the TG2-mediated HIF suppression and
TG2-mediated improvement in survival. Considering that TG2 modu-
lates many aspects of cell survival/death processes [19], it would not
be surprising if they were not directly linked. More work is required
to clarify the mechanisms by which TG2 protects cells against ische-
mic cell death. However the data we obtained using HEK-293A cells
suggest that the protection conferred by TG2 in OGD and the suppres-
sion of HIF activity are separate phenomena. Both wild type and
W241A-TG2 with NLS-tags were equally effective in suppressing
HRE activity in HEK-293A cells (Fig. 3a), although, theW241Amutant
version, and not the wild type, protected the cells in OGD (Fig. 6a).
More importantly, NLS-V5-TG2ΔCAT and NLS-V5-TG2-CAT alone
failed to diminish or facilitate OGD-induced cell death in HEK-293A
cells (Fig. 6b). However, their effect on HIF signaling was dramatically
different: while NLS-V5-TG2ΔCAT strongly suppressed HIF activity,
NLS-V5-TG2-CAT alone activated HIF (Fig. 5c). This result indicates
that the two events are not likely to be directly linked. Nonetheless,
the extent of the present data does not allow us to rule out the possi-
bility that TG2-dependent suppression of HIF is partly contributing to
TG2-mediated protection in OGD.
Although some TG2 constructs protected HEK-293A cells against
OGD-induced cell death, two of them, namely non-nuclear R580A
(Fig. 6a) and non-nuclear V5-TG2 CAT (Fig. 6b), facilitated it. The
R580 residue is located at the center of the guanine nucleotide bind-
ing site and has been shown to be indispensable for binding [19,49].
Mutation of this residue, therefore, has two important outcomes:
the mutant is more likely to exist in an open conformation (and
hence certain domains which are buried in the closed conformation
are exposed) and it exhibits a higher transamidating activity inside
the cell [19,21,49]. Therefore, the facilitation of OGD-induced cell
death by R580A (Fig. 6a) could be attributed either to this mutant's
conformation and/or its increased intracellular transamidase activity.
Interestingly, the expression of the catalytic core domain without the
NLS tag also facilitated OGD-induced cell death (Fig. 6b). The catalyticcore domain alone has no transamidating activity (Fig. 4b), but it might
present a potentially “toxic” region of the molecule due to the deletion
of the N-terminal and C-terminal domains. Unless R580A-TG2 and the
catalytic core domain exert their toxicities through different mecha-
nisms; these data suggest that the conformation, not the disinhibited
transamidating activity, of TG2 is facilitating the ODG-induced cell
death. This conclusion is also supported by our previous ﬁndings which
showed that the open conformation of TG2 exacerbated OGD-induced
cell death in an immortalized striatal cell model [23].
5. Conclusion
HIF-dependent transcription has great relevance to at least two
major pathologies: cancer [58] and stroke [59,60]. Although initial stud-
ies indicated that the HIF responsive genes were largely pro-survival,
it is now evident that the role of HIF activity in mediating cell death/
survival pathways is complex and dependent on many variables such
as cell type and duration and severity of the hypoxic episode [59–61].
Further, there are other important pathwayswhich are activated in hyp-
oxia such as NFκB and AP-1 [62–65] and modulated by TG2 [30,31,33].
Therefore it needs to be considered that the TG2-mediated modulation
of these or other pathways may also contribute to the protective role
of nuclear TG2 in ischemia and further investigations are required to de-
lineate their possible involvement.
In summary, these studies have provided signiﬁcant insights into
the TG2-mediated protection against, or facilitation of, ischemic cell
death. These ﬁndings clearly demonstrate the dual nature of the role
that TG2 plays in modulating cell death processes depending on its lo-
calization and conformation.We also provide data supporting the phys-
iological relevance of TG2 in mediating the cell's response to hypoxia,
as endogenous TG2mediates HIF activity. Our data suggest that nuclear
localization of TG2 is required for the suppression of HIF activity and
that this suppression is likely due to the direct regulation of hypoxia re-
sponsive transcription as TG2 localizes to HRE containing promoters.
Overall, it is becoming clear that an important function of TG2 is the
modulation of the transcription of hypoxic responsive genes, and that
TG2 clearly plays an important role in the complicated survival or
death decisions that occur in response to ischemic stress.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2012.10.011.
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